Last reviewed · How we verify
NCT06832293
My MS and My Menstrual Cycle
trial in Multiple Sclerosis in 300 participants. Suspended.
31 January 2027
Quick facts
| Lead sponsor | University of Alberta |
|---|---|
| Status | Suspended |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 19 February 2025 |
| Primary completion | 31 January 2027 |
| Estimated completion | 31 January 2027 |
| Sites | 2 locations across Canada |
Conditions studied
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
- Menstrual Cycle — all drugs for Menstrual Cycle →
Sponsor
University of Alberta
Who can join
16 and older, female only, with Multiple Sclerosis or Menstrual Cycle. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to understand how MS symptoms change during different phases of the menstrual cycle in individuals who menstruate living with MS (Multiple Sclerosis). The main questions it aims to answer are: 1. Does fatigue get worse during certain phases of the menstrual cycle? 2. How do symptoms like thinking skills, pain, and mobility change throughout the cycle? Participants will: * Use the My Normative app to track their menstrual cycle and MS symptoms. * Complete symptom check-ins at five points during their cycle for six months. * Answer questions about fatigue, thinking skills, mood, sleep, and other MS symptoms at the start and end of the study. These findings may help researchers better understand MS symptom patterns and improve symptom management.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06832293
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Sclerosis
Currently open trials in the same condition.
- NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
- NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
- NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting
Other University of Alberta trials
Trials by the same sponsor.
- NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
- NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
- NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
- NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
- NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06832293 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alberta
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06832293.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing